HER2-activating mutations were found to facilitate the endocytosis of the HER2-ADC complex providing a potential explanation for the higher efficacy in HER2-mutant NSCLC patients in contrast to HER2-overexpressing patients [107]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.